Immune · Immune peptide (research)
LL-37
- Drug class
- Immune peptide (research)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What LL-37 is studied for
- Antimicrobial activity (research)
- Gut health (research)
- Microbiome balance (research)
Mechanism of action
LL-37 is being studied in the immune category. Human antimicrobial peptide for gut and immune defense. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is LL-37?
LL-37 is a immune peptide. Human antimicrobial peptide for gut and immune defense.
What is LL-37 studied for?
Published research has examined LL-37 for antimicrobial activity, gut health, microbiome balance. Human clinical evidence varies by indication.
Is LL-37 FDA-approved?
No. LL-37 is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is LL-37 used in research?
Protocols vary by study. LL-37 is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for LL-37 is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.
Build the LL-37 protocol stack
Research protocols commonly pair LL-37 with the peptides below. Add all three vials to unlock the bundle discount at checkout.
Related peptides in Immune
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.